Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
The evolving promise of 
genomic medicine 
IBM Institute for Business Value 
2000 2005 2010 2015 
2001 2003 2014 
Innovati...
Upcoming SlideShare
Loading in …5
×

Infographic genomic medicine

683 views

Published on

After the Human Genome Project was completed in 2003, early successes in genomic medicine fell short of the initial
high expectations. But today, a potent mix of influences — including innovation in biology and technology, market demand and consumerism — is furthering an evolution that crosses industries. Healthcare providers can now personalize care plans thanks to lower sequencing
costs that allow genomic data to be combined with electronic health data. Life sciences companies can develop targeted therapies that prevent and alleviate disease symptoms. To capitalize on new advances
in science, cognitive computing, analytics and drug discovery, senior leaders across the ecosystem should act quickly to: make genomic medicine a key component of enterprise strategy; address relevant skill gaps; and determine how partnering can bolster critical capabilities.

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Infographic genomic medicine

  1. 1. The evolving promise of genomic medicine IBM Institute for Business Value 2000 2005 2010 2015 2001 2003 2014 Innovation in biology and technology Growing market demand for targeted products Consumerism and regulatory attention bring new media attention Announcement of Human Genome Project Human Genome Project declared complete Exploring major changes ahead from genomic medicine The growing use of a new genomic health record Opportunities for radical industry transformation across healthcare and life sciences Greater benefits for stakeholders Genomic medicine and technology improvements offer substantial benefits Translational medicine Data analytics will include cognitive computing platforms Achieve insights on with high efficacy and low side effects Share and validate insights among communities Personalized healthcare Offer faster “second opinions” with higher confidence and rigor Disease progression models will guide physicians Oncology is expected to benefit first Sequencing Becomes faster, cheaper and more accurate Aggregate and analyze information from multiple sources Analytics capabilities increase raw data's value Register to read this report: http://bit.ly/genomicpaper © Copyright IBM Corporation 2014. IBM, the IBM logo and ibm.com are trademarks or registered trademarks of IBM Corp., registered in many jurisdictions worldwide. Other product or service names might be trademarks of IBM or other companies. A current list of IBM trademarks is available on the Web at “Copyright and trademark information” at ibm.com/legal/copytrade.shtml GBL03022-USEN-00

×